Skip to main content
SpringerLink
Log in

Teratogenesis associated with antibipolar agents

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Objective

To review the teratogenic effects associated with the use of Food and Drug Administration-approved agents for bipolar disorder.

Methods

A PubMed search of all English language articles published from January 1966 to December 2008 was conducted. The key search terms included all major bipolar agents, cross-referenced with: teratogenicity, teratogen, safety, pregnancy, fetus, bipolar disorder, and malformation. The search was augmented with manual reviews of relevant article reference lists as well as http://clinicaltrials.gov and http://www.fda.gov (both last accessed in April 2008). Several pregnancy registries were also reviewed to determine malformation rates as well as teratogenesis attributable to each agent. Articles selected for review were based on author consensus, adequacy of sample size, the use of standardized experimental procedures, validated assessment measures, and overall manuscript quality.

Results

Valproate is associated with the highest rate of major congenital malformations (6.2%–16%). The relative risk of neural tube defects with valproate and carbamazepine is reported as approximately 1%–5% and 0.5%–1%, respectively. Preliminary evidence suggests that the relative risk for oral clefts (cleft lip or palate) is increased with lamotrigine relative to other antiepileptic drugs (AED) (ie, approximately 0.4%). The rate of major congenital malformations is higher in fetuses exposed to AED polytherapy (ie, ≥2 drugs) in comparison with AED monotherapy. Adverse neurobehavioral effects are insufficiently reported for most agents. In-utero exposure to valproate is associated with a greater risk of developmental difficulty requiring special education interventions as well as decreased verbal IQ scores. The risk of Ebstein’s anomaly associated with lithium use is increased relative to the general population. The major congenital malformation rate with chlorpromazine and atypical antipsychotics is not established as being higher than a non-exposed group; the teratogenic risks associated with the olanzapine-fluoxetine combination are unknown.

Conclusions

Well-characterized risks are associated with valproate, carbamazepine, lamotrigine, and lithium. The risks associated with psychotropic drug use need to be understood in the context of significant rates of relapse and associated morbidity when discontinuing bipolar treatment during pregnancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCSR). JAMA. 2003;289:3095–3105.

    Article  PubMed  Google Scholar 

  2. Tondo L, Isacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs. 2003;17:491–511.

    Article  PubMed  CAS  Google Scholar 

  3. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349:1436–1442.

    Article  PubMed  CAS  Google Scholar 

  4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: Fourth Edition Text revision (DSM-IV-TR). 4th edition. Washington: American Psychiatric Association; 2000.

    Google Scholar 

  5. McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as “Metabolic Syndrome Type II”? Ann Clin Psychiatry. 2007;19:257–264.

    Article  PubMed  Google Scholar 

  6. McIntyre RS, Konarski JZ. Bipolar disorder: a national health concern. CNS Spectr. 2004;9:6–15.

    PubMed  Google Scholar 

  7. McIntyre R, Kennedy S, Bagby RM, Bakish D. Assessing full remission. J Psychiatry Neurosci. 2002;27:235–239.

    PubMed  Google Scholar 

  8. Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164:1817–1824.

    Article  PubMed  Google Scholar 

  9. Pandarakalam JP. Clinical challenges of bipolar depression. Br J Hosp Med (Lond). 2007;68:530–537.

    Google Scholar 

  10. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry. 2002;63(suppl. 4):42–55.

    Google Scholar 

  11. Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry. 2004;161:608–620.

    Article  PubMed  Google Scholar 

  12. Yatham LN, Kennedy SH, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006;8:721–739.

    Article  PubMed  CAS  Google Scholar 

  13. Viguera AC, Koukopoulos A, Muzina DJ, et al. Teratogenicity and anticonvulsants: lessons from neurology to psychiatry. J Clin Psychiatry. 2007;68(suppl. 9):29–33.

    Google Scholar 

  14. Koren G, Cohn T, Chitayat D, et al. Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants. Am J Psychiatry. 2002;159:136–137.

    Article  PubMed  Google Scholar 

  15. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology. 2006;67:407–412.

    Article  PubMed  CAS  Google Scholar 

  16. Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr. 2004;93:174–176.

    Article  PubMed  CAS  Google Scholar 

  17. Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord. 2004;6:2–13.

    Article  PubMed  CAS  Google Scholar 

  18. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77:193–198.

    Article  PubMed  CAS  Google Scholar 

  19. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res. 1999;33:145–158.

    Article  PubMed  CAS  Google Scholar 

  20. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology. 2003;60:575–579.

    PubMed  Google Scholar 

  21. Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology. 2005;64:1874–1878.

    Article  PubMed  CAS  Google Scholar 

  22. Vajda FJ, O’Brien TJ, Hitchcock, A et al. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci. 2003;10:543–549.

    Article  PubMed  CAS  Google Scholar 

  23. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology. 2005;64:961–965.

    PubMed  CAS  Google Scholar 

  24. Vajda FJ, Eadie MJ. Maternal valproate dosage and foetal malformations. Acta Neurol Scand. 2005;112:137–143.

    Article  PubMed  CAS  Google Scholar 

  25. Vajda FJ, O’Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci. 2004;11:854–858.

    Article  PubMed  CAS  Google Scholar 

  26. Vajda FJ, Hitchcock A, Graham J, et al. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur J Neurol. 2006;13:645–654.

    Article  PubMed  CAS  Google Scholar 

  27. Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology. 2005;64:955–960.

    PubMed  CAS  Google Scholar 

  28. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med. 2001;344:1132–1138.

    Article  PubMed  CAS  Google Scholar 

  29. Samren EB, van Duijn CM, Christiaens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol. 1999;46:739–746.

    Article  PubMed  CAS  Google Scholar 

  30. Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia. 1999;40:1231–1236.

    Article  PubMed  CAS  Google Scholar 

  31. Adab N, Jacoby A, Smith D, et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2001;70:15–21.

    Article  PubMed  CAS  Google Scholar 

  32. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA. 1994;271:146–150.

    Article  PubMed  CAS  Google Scholar 

  33. Schou M, Goldfield MD, Weinstein MR, et al. Lithium and pregnancy. I. Report from the Register of Lithium Babies. Br Med J. 1973;2:135–136.

    Article  PubMed  CAS  Google Scholar 

  34. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66:444–449.

    Article  PubMed  CAS  Google Scholar 

  35. Goldstein DJ, Corbin LA, Fung MC. Olanzapineexposed pregnancies and lactation: early experience. J Clin Psychopharmacol. 2000;20:399–403.

    Article  PubMed  CAS  Google Scholar 

  36. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2004;75:1575–1583.

    Article  PubMed  CAS  Google Scholar 

  37. Vinten J, Adab N, Kini U, et al. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology. 2005;64:949–954.

    PubMed  CAS  Google Scholar 

  38. Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology. 2004;62:28–32.

    PubMed  CAS  Google Scholar 

  39. Olafsson E, Hallgrimsson JT, Hauser WA, et al. Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia. 1998;39:887–892.

    Article  PubMed  CAS  Google Scholar 

  40. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Seizure. 2008;17:166–171.

    PubMed  Google Scholar 

  41. Llewellyn A, Stowe ZN, Strader JR Jr. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry. 1998;59(suppl. 6):57–64.

    Google Scholar 

  42. Nonacs R, Cohen LS. Assessment and treatment of depression during pregnancy: an update. Psychiatr Clin North Am. 2003;26:547–562.

    Article  PubMed  Google Scholar 

  43. Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med. 1989;320:1661–1666.

    PubMed  CAS  Google Scholar 

  44. Weinstein MR. The international register of lithium babies. Drug Inf J. 1976;10:94–100.

    PubMed  CAS  Google Scholar 

  45. DiLiberti JH, Farndon PA, Dennis NR, et al. The fetal valproate syndrome. Am J Med Genet. 1984;19:473–481.

    Article  PubMed  CAS  Google Scholar 

  46. Mackay FJ, Wilton LV, Pearce GL, et al. Safety of long-term lamotrigine in epilepsy. Epilepsia. 1997;38:881–886.

    Article  PubMed  CAS  Google Scholar 

  47. CPS. Compendium of Pharmaceuticals and Specialties. Ottawa: Canadian Pharmacist Association; 2007.

    Google Scholar 

  48. Auerbach JG, Hans SL, Marcus J, et al. Maternal psychotropic medication and neonatal behavior. Neurotoxicol Teratol. 1992;14:399–406.

    Article  PubMed  CAS  Google Scholar 

  49. Ratnayake T, Libretto SE. No complications with risperidone treatment before and throughout pregnancy and during the nursing period. J Clin Psychiatry. 2002;63:76–77.

    PubMed  CAS  Google Scholar 

  50. Titze K, Koch S, Helge H, et al. Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Dev Med Child Neurol. 2008;50:117–122.

    Article  PubMed  Google Scholar 

  51. Moore SJ, Turnpenny P, Quinn A, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet. 2000;37:489–497.

    Article  PubMed  CAS  Google Scholar 

  52. Rasalam AD, Hailey H, Williams JH, et al. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol. 2005;47:551–555.

    Article  PubMed  CAS  Google Scholar 

  53. Williams PG, Hersh JH. A male with fetal valproate syndrome and autism. Dev Med Child Neurol. 1997;39:632–634.

    Article  PubMed  CAS  Google Scholar 

  54. Yerby MS. Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology. 2003;61(6 suppl. 2):S23–S26.

    Google Scholar 

  55. Viguera AC, Cohen LS. The course and management of bipolar disorder during pregnancy. Psychopharmacol Bull. 1998;34:339–346.

    PubMed  CAS  Google Scholar 

  56. Kallen AJ. Maternal carbamazepine and infant spina bifida. Reprod Toxicol. 1994;8:203–205.

    Article  PubMed  CAS  Google Scholar 

  57. Matalon S, Schechtman S, Goldzweig G, et al. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol. 2002;16:9–17.

    Article  PubMed  CAS  Google Scholar 

  58. Nulman I, Scolnik D, Chitayat D, et al. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. Am J Med Genet. 1997;68:18–24.

    Article  PubMed  CAS  Google Scholar 

  59. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med. 1991;324:674–677.

    PubMed  CAS  Google Scholar 

  60. av-Citrin O, Shechtman S, Arnon J, et al. Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology. 2001;57:321–324.

    Google Scholar 

  61. Iqbal MM, Gundlapalli SP, Ryan WG, et al. Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants. South Med J. 2001;94:304–322.

    PubMed  CAS  Google Scholar 

  62. Holmes LB, Coull BA, Dorfman J, et al. The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. J Pediatr. 2005;146:118–122.

    Article  PubMed  CAS  Google Scholar 

  63. Gentile S. Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers. Bipolar Disord. 2006;8:207–220.

    Article  PubMed  CAS  Google Scholar 

  64. Prakash, Prabhu LV, Nasar MA, et al. Lamotrigine in pregnancy: safety profile and the risk of malformations. Singapore Med J. 2007;48:880–883.

    PubMed  CAS  Google Scholar 

  65. Shor S, Koren G, Nulman I. Teratogenicity of lamotrigine. Can Fam Physician. 2007;53:1007–1009.

    PubMed  Google Scholar 

  66. Newport DJ, Stowe ZN, Viguera AC, et al. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord. 2008;10:432–436.

    Article  PubMed  CAS  Google Scholar 

  67. Newport DJ, Viguera AC, Beach AJ, et al. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry. 2005;162:2162–2170.

    Article  PubMed  Google Scholar 

  68. Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164:1214–1220.

    Article  PubMed  Google Scholar 

  69. Dube S, Tollefson GD, Thase ME, et al. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord. 2007;9:618–627.

    Article  PubMed  CAS  Google Scholar 

  70. Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356:2684–2692.

    Article  PubMed  CAS  Google Scholar 

  71. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356:2675–2683.

    Article  PubMed  CAS  Google Scholar 

  72. Eadie MJ. Antiepileptic drugs as human teratogens. Expert Opin Drug Saf. 2008;7:195–209.

    Article  PubMed  CAS  Google Scholar 

  73. Fried S, Kozer E, Nulman I, et al. Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Saf. 2004;27:197–202.

    Article  PubMed  Google Scholar 

  74. Viguera AC, Nonacs R, Cohen LS, et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry. 2000;157:179–184.

    Article  PubMed  CAS  Google Scholar 

  75. Samren EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia. 1997;38:981–990.

    Article  PubMed  CAS  Google Scholar 

  76. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001;46:273–281.

    PubMed  CAS  Google Scholar 

  77. McIntyre RS. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J Clin Psychiatry. 2002;63(suppl. 3):15–20.

    Google Scholar 

  78. Ward S, Wisner KL. Collaborative management of women with bipolar disorder during pregnancy and postpartum: pharmacologic considerations. J Midwifery Womens Health. 2007;52:3–13.

    Article  PubMed  Google Scholar 

  79. Carpenter MW. Gestational diabetes, pregnancy hypertension, and late vascular disease. Diabetes Care. 2007;30(suppl. 2):S246–S250.

    Article  CAS  Google Scholar 

  80. Carmichael SL, Shaw GM, Neri E, et al. Physical activity and risk of neural tube defects. Matern Child Health J. 2002;6:151–157.

    Article  PubMed  Google Scholar 

  81. Rambeck B, Kurlemann G, Stodieck SR, et al. Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. Eur J Clin Pharmacol. 1997;51:481–484.

    Article  PubMed  CAS  Google Scholar 

  82. Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry. 1994;45:444–450.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada

    Ha T. T. Nguyen

  2. Department of Psychiatry, University of Western Ontario, London, Ontario, Canada

    Verinder Sharma

  3. Department of Psychiatry and Department of Pharmacology, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, Ontario, Canada, M5T 2S8

    Roger S. McIntyre

Authors
  1. Ha T. T. Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Verinder Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roger S. McIntyre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger S. McIntyre.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nguyen, H.T.T., Sharma, V. & McIntyre, R.S. Teratogenesis associated with antibipolar agents. Adv Therapy 26, 281–294 (2009). https://doi.org/10.1007/s12325-009-0011-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-009-0011-z

Keywords

Search

Navigation